Abstract Parotid secretory protein (PSP) (C20orf70) is a salivary protein of unknown function. The protein belongs to the palate, lung, and nasal epithelium clone (PLUNC) family of mucosal secretory proteins that are predicted to be structurally similar to lipid-binding and host-defense proteins including bactericidal/permeability-increasing protein and lipopolysaccharide-binding protein. However, the PLUNC proteins exhibit significant sequence variation and different biological functions have been proposed for different family members. This study tested the functional implications of the proposed similarity of PSP to the acute phase protein lipopolysaccharide-binding protein (LBP). PSP was identified in human saliva and was soluble in 70% ethanol, as shown for other PLUNC proteins. PSP binds lipopolysaccharide and can be eluted by non-ionic detergent, but not by urea or high salt. A synthetic PSP peptide, GL13NH2, which corresponds to a lipopolysaccharideinhibiting peptide from LBP, inhibited the binding of lipopolysaccharide to both PSP and lipopolysaccharidebinding protein. Peptides from other regions of PSP and the control peptide polymyxin B showed no effect on the binding of PSP to lipopolysaccharide. GL13NH2 also inhibited lipopolysaccharide-stimulated secretion of tumor necrosis factor from macrophages. The other PSP peptides had no effect in this assay. PSP peptides had no or only minor effect on macrophage cell viability. These results indicate that PSP is a lipopolysaccharide-binding protein that is functionally related to LBP, as suggested by their predicted structural similarities.
Introduction
Human parotid secretory protein (hPSP) (C20orf70) is a human salivary protein that is expressed in acinar and ductal cells of the parotid gland, submandibular gland and in gingival epithelial cells [1] [2] [3] [4] . Human PSP belongs to the palate, lung, and nasal epithelium clone (PLUNC) gene family located on chromosome 20q11 [5] and is related to similar proteins expressed in salivary glands of mouse [6] , rat [7] , hamster [8] , pig [9] , horse [10] , and cattle (BSP30) [11] . A search of the NCBI data base revealed additional predicted PSP genes in dog, chimpanzee, orangutan, rhesus macaque, marmoset, and giant panda.
The PLUNC family consists of mucosal secretory proteins that are predicted to contain one or two BPI superfamily domains (NCBI CDD cl00188), which are also found in bactericidal/permeability-increasing protein (BPI), lipopolysaccharide (LPS)-binding protein (LBP), cholesteryl ester transport protein, and phospholipid transport protein [5, 12, 13] . Despite this predicted structural similarity, the PLUNC proteins exhibit significant sequence variation and different biological functions have been proposed for different family members [14] [15] [16] [17] [18] [19] [20] . In particular, human PLUNC has been found to bind LPS [19] while bovine BSP30 does not exhibit LPS-binding activity [21] . Thus, it is not clear if the proposed BPI-like structure of the PLUNC proteins has implications for biological function.
In this report we have used previously designed PSP peptides to deduce a biological function for PSP. The PSP peptide design was based on the identification of LBP peptides that inhibit LPS binding to LBP and prevent LPSinduced secretion of TNFa from macrophages [22] . Since the PSP peptides exhibit similar activities [1] , we tested whether PSP is also an LPS-binding protein. This study reports that PSP binds LPS and that binding is inhibited by the PSP peptide GL13NH2. This peptide also inhibits LPS binding to LBP and the LPS-stimulated secretion of TNF from macrophages. These findings suggest a biological function for PSP and validate the use of the proposed PSP structure for functional studies.
Materials and methods

Peptides and reagents
PSP peptides (Table 1) were synthesized by Peptides International, Louisville, Kentucky or the University of Minnesota peptide synthesis core. Polymyxin B and Pseudomonas aeruginosa LPS were from Sigma Chemical Co (St. Louis, MO). Monophosphoryl lipid A (MPLA) was from Invivogen (San Diego, CA). Control samples for the peptide experiments contained an equal volume of 0.01% acetic acid. Media and buffers were tested for LPS contamination by the limulus amebocyte lysate assay (Pyrogent Gel Clot LAL assay; Lonza, Walkersville, MD). An antiserum to human PSP was a kind gift from Dr. Thomas T. Wheeler, AgResearch, New Zealand. The antibody was validated by reaction with recombinant human PSP expressed in E. coli (not shown) or GH4C1 cells (Fig. 3b ).
Saliva samples
Saliva collection was approved by the Institutional Review Board of the University of Louisville (protocol 335.07). Whole saliva was collected on ice from healthy volunteers, using mechanical (chewing action) or citrus stimulation. Saliva was centrifuged 30 min at 3,0009g and the resulting supernatant (saliva supernatant) stored at -20°C prior to use. In some experiments, the saliva supernatant was precipitated with three volumes of cold 95% ethanol and incubated 15 min at 4°C. The samples were centrifuged at 3,0009g for 1 h and the ethanol supernatant fraction mixed with 2.5 volumes of ice-cold acetone. The samples were incubated at 4°C and centrifuged at 3,0009g for 30 min. The pellet was resuspended in PBS and stored at -20°C until use. One milliliter of this ''saliva ethanol supernatant'' corresponds to 10 ml ''saliva supernatant''.
Saliva degradation
Aliquots of saliva supernatant were incubated overnight at -20°C, 4°C, 21°C (room temperature) or 37°C. The samples were boiled in SDS-PAGE sample buffer and stored frozen until analysis.
Recombinant PSP
Human PSP was expressed in rat pituitary GH4C1 cells that were transfected with the plasmid pcDNA3 containing a wild-type human PSP cDNA under the control of the CMV promoter [2] . PSP expression was enhanced by treating the transfected cells with 5 mM sodium butyrate in DMEM [23] . Control media came from GH4C1 cells that were transfected with a plasmid containing the cDNA insert in reverse orientation, which does not allow PSP expression [2] . Secretion medium was collected after 24 h and centrifuged 10 min at 1,0009g to remove cells and cell debris before use.
LPS pull-down experiments LPS beads were prepared by coupling P. aeruginosa LPS (10 mg/ml) to CNBr-Sepharose 4 fast flow beads (GE Health Care) following the manufacturer's instructions. Saliva supernatant was diluted 1:6 in 10 mM sodium phosphate, pH 7.4. Five milliliter diluted supernatant or 5 ml GH4C1 secretion medium was mixed with a 500 ll slurry of LPS beads overnight at 4°C. The beads were centrifuged (2009g, 90 s) and washed with 3 9 0.5 or 1 ml PBS followed by elution in PBS supplemented with either 0.5 mM EDTA or 8 M urea or 1% Tween 20 or 1 M NaCl. The beads were centrifuged and the supernatants (eluate) were precipitated with 80% acetone and analyzed by SDS-PAGE and immunoblotting. Bound proteins were detected by boiling the eluted beads in SDS-PAGE sample buffer followed by SDS-PAGE and immunoblotting of the supernatant, as previously described [24] . For peptide inhibition experiments (Fig. 4a, b ), the beads (50 ll slurry) were incubated with 5 ll saliva supernatant or saliva ethanol supernatant and 100 lg/ml peptide. The volume was adjusted to 200 ll with 10 mM sodium phosphate pH 7.4 or PBS and the samples were incubated overnight at 4°C followed by washing in PBS.
Bound proteins were detected by boiling the beads in SDS-PAGE sample buffer followed by SDS-PAGE and immunoblotting of the supernatant.
LBP-binding assay
The effect of PSP peptides on the binding of LPS to LPSbinding protein was quantitated by a commercial assay (Endoblock LBP ELISA; Hycult Biotech, Uden, The Netherlands). The assay was performed according to the manufacturer's protocol using 0-180 lg/ml of the PSP peptides or polymyxin B as inhibitors. Biotinylated LPS bound to LBP was reacted with streptavidin-peroxidase and detected colorimetrically.
Tumor necrosis factor-a (TNFa) secretion assay RAW 264.7 cells were cultured in RAW medium overnight in 24-well plates as described [1] . LPS or MPLA (100 ng/ ml) and 200 lg/ml peptide were pre-incubated in RAW medium for 1 h at 37°C prior to addition to the RAW cells. The cells were then incubated overnight at 37°C, 5% CO 2 after which the media were collected, chilled on ice and centrifuged 5 min at 21,0009g. The supernatants were stored frozen or used directly for serial dilution and analysis by TNFa ELISA, following the manufacturer's instructions (eBioscience, San Diego, CA).
To test the effect of PSP peptides on the TNFa assay, TNFa ELISA standard curves were prepared in the presence of 100 lg/ml of GK7, GL13NH2 or buffer control (0.01% acetic acid). The PSP peptides did not affect the detection and quantitation of TNFa in this assay (not shown).
Viability assay RAW 264.7 cells were cultured overnight in 24-well plates as described [1] and the medium was replaced with 0.5 ml fresh RAW medium [1] containing 200 lg/ml of the PSP peptides or a buffer control. After 24 h incubation, the cellular ATP content was quantitated using the Cell Titer Glo assay (Promega, Madison, WI).
Statistical analysis
Data were analyzed by ANOVA with multiple comparison post-tests, as indicated in figure legends. P \ 0.05 was considered statistically significant.
Results
Human PSP is expressed in salivary glands as a 249 amino acid, hydrophobic glycoprotein where leucine, isoleucine, and valine constitute 34% of the amino acid residues. PSP is related to PLUNC and BSP30, which are soluble in 75% ethanol [25] and 63% isopropanol [21] , respectively. To test whether PSP is also soluble in alcohol, saliva was ethanol precipitated and analyzed by SDS-PAGE and immunoblotting (Fig. 1) . While the majority of saliva proteins, including amylase, were precipitated by 70% ethanol, PSP was largely recovered in the supernatant fraction after centrifugation of the precipitates (Fig. 1) . Thus, alcohol solubility appears to be a general property of members of the PLUNC family. Human PSP is typically identified as two bands upon SDS-PAGE, including an N-glycosylated and non-glycosylated form [2, 3, 26] . To test whether these molecular forms are susceptible to proteolytic degradation, whole saliva was incubated overnight at different temperatures. The ratio of the upper and lower PSP bands did not change, even at 37°C, suggesting that the two forms are not differentially processed by proteolysis after secretion (Fig. 2) . Based on this result, all further experiments were performed under conditions that do not cause PSP degradation.
To test whether PSP binds LPS, saliva samples were incubated with LPS-Sepharose beads and bound PSP detected by immunoblotting (Fig. 3) . PSP was eluted with 1% Tween 20 but not by 8 M urea or 1 M NaCl. The protein was partially eluted by 0.5 mM EDTA (Fig. 3a) .
To validate this binding, PSP was expressed in GH4C1 cells and the secretion medium used for LPS pull-down experiments. The bound protein was eluted with EDTA and detected by immunoblotting (Fig. 3b) . No binding was detected in medium from control cells that do not express PSP. In addition, PSP did not bind to control beads that did not contain LPS (data not shown). These results suggest that PSP mainly binds LPS by hydrophobic interactions. The finding that both PSP bands in saliva bound to LPS, suggest that N-glycosylation is not required for PSP binding [3] .
We have previously designed anti-LPS [1] and bacteria agglutinating [27] peptides based on the predicted structure of PSP. To determine whether these peptides disrupt the LPS-binding activity of PSP, we performed PSP pull-down assays in the presence of each peptide (Fig. 4a) . The agglutinating peptide, GL13NH2, inhibited the binding of PSP to LPS beads, while the peptides GK7 and KL11 had no effect. LPS binding was not inhibited by the LPSbinding peptide polymyxin B. To further test the inhibition by GL13NH2, the peptide was modified by adding or removing an amide: In one modification the Asp residue in position 11 was replaced with Asn (GL13D/N) to add an amide. In another modification the C-terminal amide was removed (GL13OH) ( Table 1) . Neither modification affected the peptide's ability to inhibit PSP binding to LPS (Fig. 4b) . To test whether the GL13 sequence acts as the LPS binding site in PSP, we attempted to generate a PSP mutant where the Leu residues of the GL13 domain were replaced by Ser residues. However, as noted with another PSP mutant [2] , the resulting protein was not expressed in detectable levels in mammalian cells, presumably due to incorrect folding and intracellular degradation (data not shown).
To determine whether GL13NH2 specifically inhibits LPS-binding to PSP, the peptide was also tested in an LPSbinding protein assay. GL13NH2 blocked the binding of LPS to LPS-binding protein in a dose-dependent manner. The LPS-binding peptide polymyxin B also blocked binding while GK7NH2 had no effect under these conditions (Fig. 5) .
The finding that GL13NH2 can block the binding of LPS to PSP and LBP, prompted us to test whether the peptide also blocks the action of LPS in cellular activation. GL13NH2 inhibited the secretion of TNFa from LPSactivated RAW 264.7 macrophage cells (Fig. 6a) . The PSP peptides did not stimulate TNFa secretion in the absence of LPS, suggesting that they do not exhibit inflammatory activity (not shown).
To test whether the effect of GL13NH2 was specific for LPS, RAW 264.7 macrophage cells were stimulated with the LPS-analog MPLA, an immune adjuvant that weakly stimulates toll-like receptor 4 [28] . MPLA-stimulated TNFa secretion was only about 10% of that of the LPSstimulated secretion and was completely inhibited by GL13NH2. In contrast, while polymyxin B inhibited TNFa secretion by about 25%, GK7 and KL11 had no effect (Fig. 6b) . The reduced TNFa secretion in peptide-treated cells was not due to peptide toxicity, since GK7, KL11, and GL13NH2 had no effect on cell viability. In contrast, polymyxin B reduced cell viability by about 75% (Fig. 7) . Similarly, GL13NH2 did not affect proliferation of RAW cells over 5 days (data not shown).
Discussion
Based on structural predictions, it has been proposed that PSP plays a role in host-defense, including the recognition of LPS [20] . However, conflicting LPS-binding results have been reported for the related proteins, PLUNC and BSP30 [19, 21, 25] . In this study, we determined that PSP binds to LPS, likely through hydrophobic interactions. Thus, the results for PSP are consistent with those for PLUNC but differ from those reported for BSP30. A possible difference in these experiments is that free PSP or PLUNC was bound to immobilized LPS, whereas The binding of LPS to PSP was inhibited by GL13 peptides but not by other PSP peptides or polymyxin B. This finding suggests that the GL13 sequence is part of the LPS binding site in PSP, although this could not be directly tested due to the lack of expression of the appropriate PSP mutant. By design, the location of GL13NH2 in the predicted structure of PSP [1] is similar to the location of an anti-LPS peptide in the structure of LBP [22] and GL13NH2 inhibited the binding of LPS to LBP. This finding validates the use of the predicted structure of PSP for functional studies.
GL13NH2 inhibited secretion of TNFa after stimulation of macrophages with both LPS and MPLA, suggesting that the peptide reacted with the lipid A portion of LPS. The GK7 peptide did not inhibit TNFa secretion in these overnight experiments performed in the presence of 10% serum, in contrast to earlier experiments performed over 6 h in DMEM [1] , Thus, only the longer GL13 peptides appear to remain active under longer-term cell culture conditions. Consistent with this, GL13 peptides, but not the GK7 peptide, were able to inhibit LPS binding to PSP. One rationale for using endogenous host-defense proteins rather than peptides from other species for the design of anti-inflammatory peptides is the potential for lower host toxicity. Indeed, GL13NH2 has shown little toxicity to mammalian cells in this and a previous report [27] . These findings provide hope that the PSP peptide may provide effective anti-inflammatory action with lower host toxicity than currently available anti-inflammatory peptides [29] .
